期刊文献+

高效液相色谱质谱串联法检测厄洛替尼血浆浓度 被引量:4

Determination of erlotinib in human plasma by HPLC-MS/MS
原文传递
导出
摘要 目的建立高效液相色谱-电喷雾串联质谱法测定人血浆中厄洛替尼的浓度。方法 血浆样品经甲醇蛋白沉淀后,以甲醇-(0.1%甲酸+5mmol.L-1 NH4Ac)(60∶40,v/v)为流动相,采用Ultimate XB-C18(4.6mm×150mm,5μm)色谱柱进行分离,流速为0.9mL·min-1,通过电喷雾离子化串联质谱,以多反应监测(MRM)方式进行检测。结果厄洛替尼的线性范围为1~2 000ng·mL-1,平均方法回收率在103.5%~109.0%,日内和日间变异均<15%。结论本法简单、快速、灵敏、重现性好,成功应用于厄洛替尼的血药浓度监测。 Objective To develop a liquid chromatography-tandem mass spectrometry to determine erlotinib in human plasma. Methods After protein precipitation with methanol, erlotinib and internal standard were chromatographically separated on an Ultimate XB C18 column (4.6 mm×150 mm, 5μm) with the mobile phase containing (0.1% formate and 5 mmol · L^-1 ammonium acetate buffer) and acetonitrile (40 : 60, v/v) at 0. 9 mL · min^-1. The electronic spray ion tandem mass spectrum with the positive mode and multitude reaction monitor (MRM) were used to detect the analytes. Results The linear range of the calibration curves was 1-2 000 ng · mL^-1 for erlotinib. The intraand interday precision was less than 15%. The methodology recovery ranged from 103.5% to 109.0%. Conclusion The present method is sensitive, effective and reliable, which has been successfully used in the pharmacokinetic studies of erlotinib after oral administration in healthy Chinese volunteers.
出处 《中南药学》 CAS 2011年第11期801-804,共4页 Central South Pharmacy
基金 广东省科技计划(编号:2010B031500031) 广州市科技计划(编号:2010YI-C931)
关键词 厄洛替尼 高效液相色谱质谱串联法 电喷雾 erlotinib liquid chromatography-tandem mass spectrometry electronic spray ion
  • 相关文献

参考文献18

  • 1NCCN Non-small Cell Lung Cancer Practice Guideline [M]. Practice Guideline in Oncology (v2), 2009: 20-21.
  • 2Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor [J]. J Clin Oncol, 2004, 22 (15): 3080-3090.
  • 3Bouchet S, Chauzit E, Ducint D, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS [J]. Clin Chim Acta, 2011, 412 (12): 11-12.
  • 4Chahbouni A, den Burger JC, Vos RM, et al. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry [J]. Ther Drug Monit, 2009, 12 (6): 683-687.
  • 5Roche S, McMahon G, Clynes M, et al. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib [J]. Chromatogr B Analyt Technol Biomed Life Sci, 2009, 877 (31): 3982- 3990.
  • 6Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non- small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR. 21 [J]. Clin Lung Cancer, 2006, 7 (6): 389-394.
  • 7Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome [J]. N Engl J Med, 2005, 353 (2):133-144.
  • 8Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [J]. N Engl J Med, 2005, 353 (2): 123-132.
  • 9Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. [J]. Cancer, 2001, 92 (6): 1525-1530.
  • 10Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlo tinib [J]. Proc Natl Aead Sci USA, 2004, 101 (36):13306-13311.

同被引文献20

  • 1郝少莉,仇农学.沉淀分离技术在蛋白质处理方面的应用[J].粮食与食品工业,2007,14(1):20-22. 被引量:13
  • 2HE S X.Chronopharmacology and Chronotherapy(时间药理学与时间治疗学)[M].Tianjin:Science Technology Press,1994:116.
  • 3Bouchet S, Chauzit E, Ducint D, et al. Simultaneous de- termination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS [J]. Clin ChimActa,2011,412(11/12) : 1 060.
  • 4Chahbouni A, den Burger JC, Vos RM, et al. Simultane- ous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry[J]. Ther Drug Monit, 2009,31(6) : 683.
  • 5Falcone A, Allegrini G, Antonuzzo A, Brunetti I, Pfanner E, Lencioni M, et al. Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery[J].Oncology, 1999, 57(3):195-201.
  • 6Filipski E, Amat S, Lemaigre G, Vincenti M, Breillout F, Lévi FA. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice[J].J Pharmacol Exp Ther, 1999, 289(1):231-235.
  • 7Hrushesky WJ, Langevin T, Kim YJ, Wood PA. Circadian dynamics of tumor necrosis factor alpha (cachectin) lethality[J].J Exp Med, 1994, 180(3):1059-1065.
  • 8Bruguerolle B, Prat M. Circadian phase dependent acute toxicity and pharmacokinetics of etidocaine in serum and brain of mice[J].J Pharm Pharmacol, 1990, 42(3):201-202.
  • 9Portaluppi F, Smolensky MH, Touitou Y. Ethics and methods for biological rhythm research on animals and human beings[J].Chronobiol Int, 2010, 27(9-10):1911-1929.
  • 10Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor[J].J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 796(1):181-188.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部